Evidence map›Paper›PMID 42778665›Full record

ArticleMolecular systems biology2026

An integrated spatially defined roadmap of normal and cancer-associated colon fibroblasts.

Emma W Viitala, Ella Salminen, Mitro Miihkinen, Toni T Lemmetyinen, Myriam Sévigny, Kiisla K Porvari, Tanisha Malpani, Niki Chalkidi, Athanasia Stavropoulou, Pekka J Päivinen and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular systems biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Emma W ViitalaMolecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland. emma.viitala@helsinki.fi.ORCID http://orcid.org/0000-0002-4526-0733
Ella Salminen *Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0009-0002-7541-0306
Mitro Miihkinen *Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0001-6822-3647
Toni T LemmetyinenMolecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-5166-7724
Myriam SévignyMolecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-1732-0583
Kiisla K PorvariMolecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0009-0005-1030-8230
Tanisha MalpaniInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0009-0007-8065-8492
Niki ChalkidiInstitute for Fundamental Biomedical Research, Biomedical Sciences Research Center Alexander Fleming, Vari, Greece.
Athanasia StavropoulouInstitute for Fundamental Biomedical Research, Biomedical Sciences Research Center Alexander Fleming, Vari, Greece.
Pekka J PäivineniCAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID http://orcid.org/0000-0001-9749-2547
Tuomas KaprioTranslational Cancer Medicine Program, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-0377-9975
Jaana HagströmTranslational Cancer Medicine Program, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0001-6079-7881
Caj HaglundTranslational Cancer Medicine Program, University of Helsinki, Helsinki, Finland.
Tomi P MäkeläiCAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Pekka KatajistoMolecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-3033-4189
Tero AittokallioInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-0886-9769
Vasiliki KoliarakiInstitute for Fundamental Biomedical Research, Biomedical Sciences Research Center Alexander Fleming, Vari, Greece.ORCID http://orcid.org/0000-0003-1694-6987
Saara OllilaMolecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland. saara.ollila@helsinki.fi.ORCID http://orcid.org/0000-0002-8190-257X

Funding

Research Council of Finland (AKA) 31729Research Council of Finland (AKA) 340141,344698Research Council of Finland (AKA) 346555The Hellenic Foundation of Research and Innovation 3001The Research Council of Norway 357096Worldwide Cancer Research (WCR) 22-0126
6 · The paper itself

Abstract

Cancer-associated fibroblasts (CAFs) promote tumorigenesis and represent potential therapeutic targets, highlighting the need for precise understanding of CAF heterogeneity. In colorectal cancer (CRC), CAF subsets and nomenclature vary widely, and many studies overlook the diversity of normal colon fibroblasts that shapes tumor mesenchyme. Here, we combine large-scale single-cell RNA-sequencing analysis with spatial validation and functional assays to construct a comprehensive reference map of human normal colon fibroblasts and mesenchymal subsets, guided by the well-characterized mouse colon. We define three major fibroblast populations, subepithelial myofibroblasts (SEMFs), mucosa-associated fibroblasts (MAFs), and submucosa-associated fibroblasts (SAFs), and characterize a previously underexplored muscle-embedded interstitial fibroblast (MIF) population. This reference enabled mapping of CRC-specific changes, revealing four cancer-specific CAF subsets, including inflammatory CAFs (iCAFs), matrix CAFs (mCAFs), and two precursor populations (pre-CAFs). We also identify robust CRC CAF markers including CTHRC1, infer transcriptional regulators, and define distinct developmental trajectories driving iCAF and mCAF activation. Together, our study provides a spatially and transcriptionally resolved reference map of fibroblasts in the normal colon and CRC, enabling mechanistic studies and informing CAF-targeted therapies.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.